An Introduction to Obesity
The prevalence of obesity is increasing worldwide and along with it the economic burden of obesity-related complications. Several pharmacotherapies have been approved to, suppress appetite and reduce lipid absorption, although lifestyle and behavioural changes remain the mainstay of the treatment paradigm. Research into SGLT-2 inhibitors, amylin mimetics, leptin analogues and ghrelin antagonists as potential treatments are ongoing.
Browse our gallery of video highlights and short articles from the conference hub, providing the latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.
The Important Role of Intermuscular Adipose Tissue on Metabolic Changes Interconnecting Obesity, Ageing and Exercise: A Systematic Review
touchREVIEWS in Endocrinology. 2023;19(1):54-9 DOI: https://doi.org/10.17925/EE.2023.19.1.54
Obesity is related to an increased risk of metabolic disease.1 It is well established that excessive body fat is related to increased morbidity and mortality and is associated with inflammation and endothelial damage.2,3 With age, fat infiltration occurs in the muscle, leading to sarcopenia. The association of the excessive accumulation of adipose tissue with a progressive decrease […]
Domenica Rubino, EASD 2022: The role of semaglutide in the treatment paradigm for prediabetes
Semaglutide has clinically beneficial effects on glucose metabolism and glycaemic status in patients with obesity and prediabetes. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses her thoughts on the role of semaglutide in the treatment paradigm for prediabetes. The abstract entitled: ‘Semaglutide 2.4 mg […]
Domenica Rubino, EASD 2022: Semaglutide 2.4 mg vs liraglutide 3.0 mg on glucose metabolism – STEP 8 post-hoc analysis
The aim of the STEP 8 trial (NCT04074161) was to compare the effect and safety of semaglutide 2.4 mg once weekly compared to liraglutide 3.0 mg once daily on weight management in people with obesity. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses the […]
Uberto Pagotto, ESPE 2022: GLP-1 agonists and other emerging treatments of obesity
Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity. In this touchENDOCRINOLOGY interview, Prof. Uberto Pagotto (University of Bologna, Bologna, Italy) discusses the impact of glucagon-like peptide 1 agonists on obesity, what other emerging treatments in obesity appear promising. The future direction in obesity research is […]
Uberto Pagotto, ESPE 2022: The global health burden and challenges of obesity
Paediatric obesity is a major threat to health and longevity. Around 7% of children worldwide have early onset severe obesity before the age of 7. In this touchENDOCRINOLOGY interview, Prof. Uberto Pagotto (IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy) discusses the global health burden of obesity as well as the challenged obesity comes with. The […]
Timothy Garvey, EASD 2022: STEP clinical trial programme: Semaglutide 2.4 mg treatment in people with obestiy
The effect of once-weekly semaglutide 2.4 mg on the risk of developing type 2 diabetes (T2D) in people with obesity is unknown. Using data from the Semaglutide Treatment Effect in People with obesity (STEP) programme (STEP 1 and STEP 4) the risk of developing T2D over 10 years was assessed. In this touchENDOCRINOLOGY interview, Prof. Timothy […]
Timothy Garvey, EASD 2022: The risk of developing type 2 diabetes in people with obesity
Obesity is the leading risk factor for type 2 diabetes. Obesity causes increased levels of fatty acids and inflammation, leading to insulin resistance. In this touchENDOCRINOLOGY interview, Prof. Timothy Garvey (University of Alabama, Birmingham, AL, USA) discusses this risk of developing type 2 diabetes in people with obesity. The abstract entitled: ‘Semaglutide 2.4 mg reduces the 10-year […]
Osama Hamdy, ADA 2022: Phenotypes and target options in diabetes
The 82nd ADA meeting, June 3-7, 2022, hosted a debate surrounding targets for diabetes management being body weight or glycaemic control. Dr Osama Hamdy (Joslin Diabetes Center, Boston, MA, USA) discusses the array of phenotypes with which diabetes presents, with precision medicine being the ultimate goal. Questions: What were your highlights of this year’s meeting? […]
Osama Hamdy, ADA 2022: Tirzepatide for obesity in the SURMOUNT-1 study and remission in type 2 diabetes
The results of SURMOUNT-1, the first phase 3 trial with the novel GIP/GLP-1 receptor agonist tirzepatide for obesity, is discussed by Dr Osama Hamdy (Joslin Diabetes Center, Boston, MA, USA) as well as key data on remission, a key theme at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022. Questions: What were the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!